Tufts CSDD Demonstrates Multi-Million-Dollar Benefits of Translational Pharmaceutics®
This webinar will summarize the key findings of the recent Tufts CSDD research into Translational Pharmaceutics, the innovative approach to drug development. It demonstrates significant time savings of >12 months and financial gains of >$100 million per drug approved.
Translational Pharmaceutics innovates the way you design and implement your drug development program and is proven to reduce drug development costs and shorten timelines.
From preclinical and first-in-human (FIH) dosage forms to optimization of your drug products for late stage development, we work with you to develop the most appropriate formulation.
When you are looking for a partner who is dedicated to Phase I trials and early development, rely on Quotient Sciences. We accelerate your molecule from first-in-human to proof-of-concept, helping you make critical decisions earlier.
Ask us a question